Skip to main content
SpringerLink
Log in

Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients

  • Review article
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life and is perceived by patients as a major adverse effect of the treatment. This review summarizes the safety and efficacy of current antiemetic agents for the prevention of CINV in children. Information on antiemetic prophylaxis for CINV in children was obtained from a literature review of current peer-reviewed articles and recent international guidelines. The literature review and the international antiemetic guidelines provide recommendations for use of specific antiemetics in children based on the emetogenicity of the chemotherapy. 5-Hydroxytryptamine-3 (5-HT3) receptor antagonists have been safe and effective in the prevention of acute emesis with a few patients experiencing mild headache. No adequate studies have been conducted to date for specific recommendations for the prevention of delayed nausea and vomiting in children. The neurokinin (NK)-1 receptor antagonist aprepitant has been approved by the US FDA for use in children of a specific age and weight. No studies for the NK1 receptor antagonists netupitant and rolapitant in children have been conducted. Olanzapine, an antipsychotic, has been shown to be safe and effective in preventing nausea and emesis in adult patients receiving chemotherapy. Its use in children has been limited to children with poor control of CINV; more studies are necessary in this population. In conclusion, practitioners should follow international antiemetic guidelines to provide patients with the specific antiemetics in the recommended dose for the highest possible quality of care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;374:1356–67.

    Article  CAS  PubMed  Google Scholar 

  2. Navari RM. Management of chemotherapy-induced nausea and vomiting: focus on new agents and new uses for older agents. Drugs. 2013;73:249–62.

    Article  CAS  PubMed  Google Scholar 

  3. Dupuis LL, Boodhan Sung, et al. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2011;57:191–8.

    Article  PubMed  Google Scholar 

  4. Dupuis LL, Sung L, Moassiotis A, et al. 2016 updated MASCC/ESMO consensus recommendations: prevention of chemotherapy-induced nausea and vomiting in children. Support Care Cancer. 2017;25:323–31.

    Article  PubMed  Google Scholar 

  5. Jordan K, Roila F, Molassiotis A, et al. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009. Support Care Cancer. 2011;19:537–42.

    Article  Google Scholar 

  6. Dupuis LL, Boodham S, Holdsworth M et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medications in pediatric cancer patients. Pediatr Blood Cancer 2013;60:1073-82.

    Article  PubMed  Google Scholar 

  7. Navari RM. Treatment of chemotherapy-induced nausea. Community Oncol. 2012;9:20–6.

    Article  Google Scholar 

  8. Navari RM, Qin R, Ruddy RJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375:134–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Stern RM, Koch KL, Andrews PLR, editors. Nausea: mechanisms and management. New York: Oxford University Press; 2011.

    Google Scholar 

  10. Lau Moon Lin M, Robinson PD, Flank J, et al. The safety of prochlorperazine in children: a systematic review and meta-analysis. Drug Saf. 2016;39:509–16.

    Article  PubMed  Google Scholar 

  11. Simpson K, Spencer CM, McClellan KJ. Topisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs. 2000;59:1297–315.

    Article  CAS  PubMed  Google Scholar 

  12. Kimura E, Niimi E, Watanabe A, et al. Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP. Gan To Kagaku Ryoho. 1996;23:477–81.

    CAS  PubMed  Google Scholar 

  13. Taguchi T, Tsukamoto F, Watanabe T, et al. Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer. Gan To Kagaku Ryoho. 1999;26:1163–70.

    CAS  PubMed  Google Scholar 

  14. Hesketh PJ. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting. Cancer Invest. 2000;18:163–73.

    Article  CAS  PubMed  Google Scholar 

  15. Phillips RS, Friend AJ, Gibson F, et al. Antiemetic medication for the prevention and treatment of chemotherapy-induced nausea and vomiting in childhood. Cochrane Database Syst Rev. 2016;2:CD007786.

    PubMed  Google Scholar 

  16. World Health Organization. Dolasetron mesylate and serious cardiovascular reactions. WHO Drug Information. 2006;20(3):185.

    Google Scholar 

  17. US Food and Drug Administration. FDA drug safety communication: abnormal heart rhythms associated with use of anzemet (dolasetron mesylate). https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020623s009lbl.pdf. Accessed 21 Mar 2017.

  18. Ondansetron: New Dose Restrictions. Prescriber Update 33(3):21. September 2012. http://www.medsafe.govt.nz/profs/PUArticles/OndansetronSept2012.htm. Accessed 23 Mar 2017.

  19. Freedman SB, Uleryk E, Rumantir M, et al. Ondansetron and the risk of cardiac arrhythmias: a systematic review and post marketing analysis. Ann Emerg Med. 2014;64:19–25.

    Article  PubMed  Google Scholar 

  20. Yeh YC, Blouin GC, Reddy P. Evidence to support use of palonosetron over generic serotonin type-3 receptor antagonists for chemotherapy-induced nausea and vomiting. Am J Health Syst Pharm. 2014;71:500–6.

    Article  CAS  PubMed  Google Scholar 

  21. Navari RM. The current status of the use of palonosetron. Expert Opin Pharmacother. 2013;14:1281–4.

    Article  CAS  PubMed  Google Scholar 

  22. Navari RM. Palonosetron for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2015;15:2599–608.

    Article  Google Scholar 

  23. Rojas C, Thomas AG, Alt J, et al. Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol. 2010;626:193–9.

    Article  CAS  PubMed  Google Scholar 

  24. Kovacs G, Wachtel AE, Basharova EV, et al. Palonosetron versus ondansetron for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomized, phase 3, double blind, double dummy, non-inferiority study. Lancet Oncol. 2016;17:332–44.

    Article  CAS  PubMed  Google Scholar 

  25. Lau Moon Lin M, Robinson PD, Flank J, et al. The safety of metoclopramide in children: a systematic review and meta-analysis. Drug Saf. 2016;39:675–87.

    Article  PubMed  Google Scholar 

  26. European Medicine Agency. Metoclopramide use recommendations. London: EMA; 26 July 2013. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/. Accessed 23 Mar 2017.

  27. Flank J, Robinson PD, Holdsworth M, et al. Guidelines for the treatment of breakthrough and the prevention of refractory chemotherapy-induced nausea and vomiting in children with cancer. Pediatr Blood Cancer. 2016;63:1144–51.

    Article  PubMed  Google Scholar 

  28. Bakhshi S, Batra A, Biswas B, et al. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer. 2015;23:3229–37.

    Article  PubMed  Google Scholar 

  29. Kang HJ, Loftus S, Taylor A, et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomized, double-blind, phase 3 trial. Lancet Oncol. 2015;16:585–94.

    Article  Google Scholar 

  30. Navari RM. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs. 2007;16:1977–85.

    Article  CAS  PubMed  Google Scholar 

  31. Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol—EASE. J Clin Oncol. 2011;29:1495–501.

    Article  CAS  PubMed  Google Scholar 

  32. Shillingburg A, Biondo L. Aprepitant and fosaprepitant use in children and adolescence at an academic medical center. J Pediatr Pharmacol Ther. 2014;19:127–31.

    PubMed  PubMed Central  Google Scholar 

  33. Aapro M, Carides A, Rapoport BL, et al. Aprepitant and fosaprepitant: a 10 year review of efficacy and safety. Oncologist. 2015;20:450–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Navari RM. Profile of netupitant/palonosetron fixed dose combination (NEPA) and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Devel Ther. 2015;9:155–61.

    PubMed  Google Scholar 

  35. Navari RM. Rolapitant for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2015;15:1127–33.

    Article  CAS  PubMed  Google Scholar 

  36. Fulton B, Goa KL. Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs. 1997;53:281–98.

    Article  CAS  PubMed  Google Scholar 

  37. Bymaster FP, Calligaro D, Falcone J. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14:87–96.

    Article  CAS  PubMed  Google Scholar 

  38. Stephenson CME, Pilowsky LS. Psychopharmacology of olanzapine: a review. Br J Psychiatry. 1999;174:52–8.

    Google Scholar 

  39. Breithart W, Tremblay A, Gibson C. An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients. Psychosomatics. 2002;43:175–82.

    Article  Google Scholar 

  40. Bymaster FP, Falcone JF, Bauzon D, et al. Potent antagonism of 5-HT (3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol. 2001;430:341–9.

    Article  CAS  PubMed  Google Scholar 

  41. Rudd JA, Ngan MP, Wai MK, et al. Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Neurosci Lett. 2006;392:79–83.

    Article  CAS  PubMed  Google Scholar 

  42. Yakabi K, Sadakane C, Noguchi M, et al. Reduced ghrelin secretion in the hypothalamus of rats due to cisplatin-induced anorexia. Endocrinology. 2010;151:3773–82.

    Article  CAS  PubMed  Google Scholar 

  43. Hurren KM, Berlie HD. Lorcaserin: an investigational serotonin 2C agonist for weight loss. Am J Health Syst Pharm. 2011;68:2029–37.

    Article  CAS  PubMed  Google Scholar 

  44. Allison DB, Casey DE. Antipsychotic-associated weight gain: A review of the literature. J Clin Psychiatry. 2001;62:22–31.

    CAS  PubMed  Google Scholar 

  45. Hale AS. Olanzapine. Br J Hosp Med. 1997;58:443–5.

    Google Scholar 

  46. Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics. 1999;40:438–43.

    Article  CAS  PubMed  Google Scholar 

  47. Flank J, Thackray J, Nielson D, et al. Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: a retrospective, multi-center review. Pediatr Blood Cancer. 2016;62:496–501.

    Article  Google Scholar 

  48. Flank J, Sung L, Dvorak C, et al. The safety of olanzapine in young children. A systematic review and meta-analysis. Drug Saf. 2014;37:791–804.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology Oncology, School of Medicine, University of Alabama Birmingham, 1802 Sixth Avenue South, North Pavillion 2540K, Birmingham, AL, 35294, USA

    Rudolph M. Navari

Authors
  1. Rudolph M. Navari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rudolph M. Navari.

Ethics declarations

Funding

No sources of funding were used to conduct this study or prepare this manuscript.

Conflict of interest

Rudolph M. Navari has no conflicts of interest that are directly relevant to the content of this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Navari, R.M. Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients. Pediatr Drugs 19, 213–222 (2017). https://doi.org/10.1007/s40272-017-0228-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40272-017-0228-2

Keywords

Search

Navigation